# Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal

Source: https://onco.cc/trials/nct07150403/  
OnCo record `nct07150403` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of leucovorin (folinic acid), fOLFIRI (5-FU, leucovorin, irinotecan), fruquintinib and bevacizumab (glioblastoma use) in colorectal cancer, run by Federation Francophone de Cancerologie Digestive, not yet recruiting.

## Summary

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07150403 by Federation Francophone de Cancerologie Digestive, with a registry enrolment figure of 74 participants, started 2025-12-31 and due to reach its primary completion in 2028-02-28. Interventions recorded: Oxaliplatin intravenous; 5 FU bolus; Folinic acid; 5 FU continuous; Irinotecan; FRUQUINTINIB; BEVACIZUMAB. Conditions listed: Metastatic Colorectal Carcinoma (mCRC). Primary outcome: Disease Control Rate (DCR). Colorectal eligibility wording from the registry: "* Patients with a histologically confirmed diagnosis of metastatic colorectal cancer (mCRC), with a documented disease progression (as per RECIST v1". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07150403
- Phase: 2
- Setting: A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
- Sponsor: Federation Francophone de Cancerologie Digestive
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT07150403: https://clinicaltrials.gov/study/NCT07150403

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07150403.json